TransMedics Group, Inc. (TMDX) compounding analysis
Full-size annual and quarterly year-over-year growth charts for revenue, EPS, operating cash flow, EBITDA, and free cash flow against the 15%, 20%, and 30% bars over 3-, 5-, and 10-year windows, with each metric's valuation multiple vs its own history.
Revenue · 5YClears the 15%+ and 20%+ revenue bars over 5Y.
- Score
- 63/100
- 5Y CAGR
- 88.2%
- Median YoY
- 121.5%
- YoY volatility
- σ 91.1pp· choppy
- Quarters ≥ 20%
- 19 of 20
- Negative quarters
- 1
- Valuation vs own 5Y history
- P/S 3.9x · 5Y median 14.6x · 5th percentile
How this score is computed
- Quarters at or above 20%: 19 of 20 → 38 of 40 pts
- Steadiness (typical swing 91.1pp) → 0 of 25 pts
- Pace (median 121.5% YoY) → 20 of 20 pts
- Latest quarter (21.2% YoY) → 4.6 of 15 pts
- Score: 63 of 100
Annual revenue · last 10 fiscal years
Quarterly YoY revenue growth vs the 20% line · 5Y
P/S multiple vs its 5Y median · context only
Across metrics · 5Y
| Metric | 5Y CAGR | Median YoY | YoY σ | Qtrs ≥ 20% | Neg. qtrs |
|---|---|---|---|---|---|
| RevenueRevenue | 88.2% | 121.5% | 91.1pp | 19 of 20 | 1 |
| EPSEPS | — | — | — | — | — |
| Op cash flowOperating cash flow | — | — | — | — | — |
| EBITDAEBITDA | — | — | — | — | — |
| FCFFree cash flow | — | — | — | — | — |
Reported figures over 5Y: annual-series CAGR, median and standard deviation (σ, percentage points) of quarterly year-over-year growth, quarters at or above 20%, and quarters with negative YoY. “—” means the window needs more comparable data.
Scores, qualification bars, and the 0–100 consistency methodology are documented on the compounders list page →
See also: TMDX on the compounders surface · All compounders, ranked
About TransMedics Group, Inc.
TransMedics Group, Inc. operates as a commercial-stage medical technology enterprise, committed to transforming the landscape of organ transplant therapy for patients worldwide grappling with end-stage organ failure. At the core of their offerings is the Organ Care System (OCS), an innovative, portable solution engineered to perfuse, optimize, and continuously monitor donor organs. This system leverages exclusive, tailored technology to meticulously recreate near-physiological conditions for these vital organs while they remain outside the human body. The OCS suite encompasses specialized modules: OCS LUNG, which facilitates the preservation of standard criteria donor lungs for double-lung transplants; OCS Heart, designed for the extracorporeal perfusion and maintenance of donor hearts; and OCS Liver, dedicated to the preservation of donor livers. Founded in 1998, TransMedics is headquartered in Andover, Massachusetts.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Waleed H. Hassanein